Concepts (88)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 9 | 2023 | 609 | 1.110 |
Why?
|
| Telemedicine | 3 | 2023 | 117 | 0.880 |
Why?
|
| Neurology | 2 | 2019 | 48 | 0.690 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2018 | 5 | 0.570 |
Why?
|
| Secondary Prevention | 1 | 2017 | 65 | 0.500 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 157 | 0.500 |
Why?
|
| Hypertension | 1 | 2017 | 976 | 0.310 |
Why?
|
| Tissue Plasminogen Activator | 4 | 2014 | 41 | 0.250 |
Why?
|
| Thrombolytic Therapy | 3 | 2014 | 64 | 0.230 |
Why?
|
| Fibrinolytic Agents | 3 | 2014 | 69 | 0.230 |
Why?
|
| Vertebrobasilar Insufficiency | 1 | 2023 | 7 | 0.200 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2023 | 36 | 0.200 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2020 | 34 | 0.160 |
Why?
|
| Ischemic Attack, Transient | 1 | 2020 | 48 | 0.160 |
Why?
|
| Electroencephalography | 1 | 2018 | 72 | 0.140 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 490 | 0.130 |
Why?
|
| Aged | 6 | 2023 | 10538 | 0.120 |
Why?
|
| Humans | 10 | 2023 | 32798 | 0.120 |
Why?
|
| Severity of Illness Index | 3 | 2013 | 881 | 0.120 |
Why?
|
| Eligibility Determination | 1 | 2014 | 18 | 0.110 |
Why?
|
| Risk Factors | 3 | 2017 | 3974 | 0.100 |
Why?
|
| Teleradiology | 1 | 2013 | 1 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 1307 | 0.090 |
Why?
|
| Brain Ischemia | 1 | 2013 | 147 | 0.090 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 754 | 0.090 |
Why?
|
| United States | 1 | 2019 | 4108 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 947 | 0.070 |
Why?
|
| Aging | 1 | 2014 | 938 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2023 | 767 | 0.060 |
Why?
|
| Female | 4 | 2018 | 20261 | 0.060 |
Why?
|
| Referral and Consultation | 2 | 2020 | 147 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2023 | 3438 | 0.060 |
Why?
|
| Dendrites | 1 | 2004 | 16 | 0.050 |
Why?
|
| Endoplasmic Reticulum | 1 | 2004 | 23 | 0.050 |
Why?
|
| Glycine | 1 | 2004 | 27 | 0.050 |
Why?
|
| Recombinant Proteins | 2 | 2014 | 247 | 0.050 |
Why?
|
| Basilar Artery | 1 | 2023 | 9 | 0.050 |
Why?
|
| Perfusion | 1 | 2023 | 74 | 0.050 |
Why?
|
| Thrombectomy | 1 | 2023 | 75 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2014 | 4032 | 0.040 |
Why?
|
| Survivors | 1 | 2023 | 168 | 0.040 |
Why?
|
| Workflow | 1 | 2020 | 20 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2020 | 91 | 0.040 |
Why?
|
| Quality Indicators, Health Care | 1 | 2020 | 60 | 0.040 |
Why?
|
| Leadership | 1 | 2020 | 40 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2020 | 272 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2020 | 204 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 188 | 0.040 |
Why?
|
| Time Factors | 2 | 2014 | 2183 | 0.040 |
Why?
|
| Prognosis | 2 | 2013 | 1544 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 360 | 0.030 |
Why?
|
| Middle Aged | 3 | 2014 | 12125 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2023 | 3701 | 0.030 |
Why?
|
| Review Literature as Topic | 1 | 2014 | 8 | 0.030 |
Why?
|
| Data Collection | 1 | 2014 | 185 | 0.030 |
Why?
|
| Neurologic Examination | 1 | 2013 | 28 | 0.030 |
Why?
|
| California | 1 | 2013 | 66 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 97 | 0.030 |
Why?
|
| Observer Variation | 1 | 2013 | 96 | 0.020 |
Why?
|
| Glasgow Outcome Scale | 1 | 2012 | 2 | 0.020 |
Why?
|
| Telephone | 1 | 2013 | 58 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2013 | 203 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2013 | 238 | 0.020 |
Why?
|
| Cerebral Hemorrhage | 1 | 2012 | 70 | 0.020 |
Why?
|
| Physicians | 1 | 2014 | 165 | 0.020 |
Why?
|
| Male | 3 | 2014 | 19641 | 0.020 |
Why?
|
| Patient Selection | 1 | 2013 | 281 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2012 | 525 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 887 | 0.020 |
Why?
|
| Age Factors | 1 | 2012 | 1197 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2013 | 2327 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2013 | 1460 | 0.020 |
Why?
|
| COP-Coated Vesicles | 1 | 2004 | 1 | 0.010 |
Why?
|
| Excitatory Amino Acid Agents | 1 | 2004 | 3 | 0.010 |
Why?
|
| Resorcinols | 1 | 2004 | 6 | 0.010 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2004 | 6 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 2004 | 15 | 0.010 |
Why?
|
| Nuclear Pore Complex Proteins | 1 | 2004 | 5 | 0.010 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2004 | 17 | 0.010 |
Why?
|
| Cell Membrane Permeability | 1 | 2004 | 18 | 0.010 |
Why?
|
| Protein Transport | 1 | 2004 | 72 | 0.010 |
Why?
|
| Receptors, Metabotropic Glutamate | 1 | 2004 | 23 | 0.010 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2004 | 36 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2004 | 251 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2004 | 820 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2004 | 754 | 0.010 |
Why?
|
| Rats | 1 | 2004 | 1606 | 0.010 |
Why?
|
| Animals | 1 | 2004 | 7569 | 0.010 |
Why?
|